<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35337040</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Protection of Ducklings from Duck Hepatitis A Virus Infection with ELPylated Duck Interferon-α.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">633</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v14030633</ELocationID><Abstract><AbstractText>Duck viral hepatitis type I (DVH I) is a lethal disease in ducklings caused by duck hepatitis A virus (DHAV). Although the commercial vaccine is available for vaccination of one-day-old ducklings or breeder ducks, the disease is still prevalent due to the delayed immune response in ducklings and variable maternal antibody levels in breeder duck flocks. To explore the feasibility of duck interferon-α (DuIFN-α) for control of DVH I, DuIFN-α was expressed as an elastin-like polypeptide (ELP) fusion protein (ELP-DuIFN-α) in E. coli and purified by inverse phase transition cycling (ITC). After detection of its cytotoxicity, bioactivity, plasma stability and serum half-life, the protective efficacy of ELP-DuIFN-α against DHAV-1 infection of embryos or ducklings was evaluated using different treatment routes at different infection times. The results show that ELP-DuIFN-α was correctly expressed and purified to more than 90% purity after two cycles of ITC. The purified fusion protein had a specific anti-DHAV-1 activity of 6.0 × 104 IU/mg protein, significantly extended plasma stability and serum half-life without overt cytotoxicity. After allantoic injection with ELP-DuIFN-α pre-infection, co-infection or post-infection with DHAV-1, 5/5, 5/5 or 4/5 embryos survived from the virus challenge. After intramuscular injection or oral administration with ELP-DuIFN-α, 3/5 or 4/5 ducklings survived from co-infection with DHAV-1. After oral administration with ELP-DuIFN-α pre-infection, co-infection or post-infection with DHAV-1, 3/5, 4/5 or 4/5 ducklings survived from the virus challenge, and the relative transcription levels of interferon-stimulated genes were significantly higher than the normal control group and virus challenge control group (p &lt; 0.01). These experimental data suggest that ELP-DuIFN-α can be used as a long-lasting anti-DHAV-1 reagent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yongjuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225300, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yanli</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225300, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haowei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225300, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225300, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Weiming</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225300, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Huaichang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225300, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Veterinary Medicine, Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Shanyuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225300, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004372" MajorTopicYN="N">Ducks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006506" MajorTopicYN="Y">Hepatitis A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030041" MajorTopicYN="Y">Hepatitis A virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004371" MajorTopicYN="Y">Hepatitis Virus, Duck</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006524" MajorTopicYN="Y">Hepatitis, Viral, Animal</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010850" MajorTopicYN="Y">Picornaviridae Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011201" MajorTopicYN="Y">Poultry Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral reagent</Keyword><Keyword MajorTopicYN="N">duck interferon-α</Keyword><Keyword MajorTopicYN="N">duck viral hepatitis</Keyword><Keyword MajorTopicYN="N">elastin-like polypeptide</Keyword><Keyword MajorTopicYN="N">fusion expression</Keyword><Keyword MajorTopicYN="N">interferon-stimulated gene</Keyword></KeywordList><CoiStatement>The authors declare that they have no potential conflict of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35337040</ArticleId><ArticleId IdType="pmc">PMC8949671</ArticleId><ArticleId IdType="doi">10.3390/v14030633</ArticleId><ArticleId IdType="pii">v14030633</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shen Y., Cheng A., Wang M., Chen S., Jia R., Zhu D., Liu M., Sun K., Yang Q., Chen X. Development of an indirect ELISA method based on the VP3 protein of duck hepatitis A virus type 1 (DHAV-1) for dual detection of DHAV-1 and DHAV-3 antibodies. J. Virol. Methods. 2015;225:30–34. doi: 10.1016/j.jviromet.2015.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2015.08.016</ArticleId><ArticleId IdType="pubmed">26341062</ArticleId></ArticleIdList></Reference><Reference><Citation>Yugo D.M., Hauck R., Shivaprasad H.L., Meng X.-J. Hepatitis Virus Infections in Poultry. Avian Dis. 2016;60:576–588. doi: 10.1637/11229-070515-Review.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1637/11229-070515-Review.1</ArticleId><ArticleId IdType="pubmed">27610716</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.-L., Xu Q., Zhang R.-H., Yang L., Li J.-X., Xie Z.-J., Zhu Y.-L., Jiang S.-J., Si X.-K. Improved duplex RT-PCR assay for differential diagnosis of mixed infection of duck hepatitis A virus type 1 and type 3 in ducklings. J. Virol. Methods. 2013;192:12–17. doi: 10.1016/j.jviromet.2013.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2013.04.012</ArticleId><ArticleId IdType="pubmed">23624117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S.-L., Cong R.-C., Zhang R.-H., Chen J.-H., Xia L.-L., Xie Z.-J., Wang Y., Zhu Y.-L., Jiang S.-J. Circulation and in vivo distribution of duck hepatitis A virus types 1 and 3 in infected ducklings. Arch. Virol. 2015;161:405–416. doi: 10.1007/s00705-015-2648-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-015-2648-z</ArticleId><ArticleId IdType="pubmed">26597185</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman M., Alfajaro M.M., Lee M.-H., Jeong Y.-J., Kim D.-S., Deok-Song K., Kwon J., Choi J.-S., Lim J.-S., Lee T.-U., et al. The prevalence of duck hepatitis A virus types 1 and 3 on Korean duck farms. Arch. Virol. 2014;160:493–498. doi: 10.1007/s00705-014-2264-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-014-2264-3</ArticleId><ArticleId IdType="pubmed">25359107</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M.C., Kim M.J., Kwon Y.K., Lindberg A.M., Joh S.J., Kwon H.M., Li Y.J., Kwon J.H. Development of duck hepatitis A virus type 3 vaccine and its use to protect ducklings against infections. Vaccine. 2009;27:6688–6694. doi: 10.1016/j.vaccine.2009.08.092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.08.092</ArticleId><ArticleId IdType="pubmed">19747575</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H., Bai J., Wang J., He M., Xiong W., Yuan W., Qiao M., Ming K., Wu Y., Wang D., et al. Assessment of the hepatocyte protective effects of gypenoside and its phosphorylated derivative against DHAV-1 infection on duck embryonic hepatocytes. BMC Veter. Res. 2019;15:134–145. doi: 10.1186/s12917-019-1891-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12917-019-1891-z</ArticleId><ArticleId IdType="pmc">PMC6505245</ArticleId><ArticleId IdType="pubmed">31064364</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayan R., Buronfosse T., Schultz U., Chevallier-Gueyron P., Guerret S., Chevallier M., Saade F., Ndeboko B., Trepo C., Zoulim F., et al. Rise in gamma interferon expression during resolution of duck hepatitis B virus infection. J. Gen. Virol. 2006;87:3225–3232. doi: 10.1099/vir.0.82170-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.82170-0</ArticleId><ArticleId IdType="pubmed">17030856</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao H. New characteristics and prevention strategies of duck disease. J. Anim. Husb. Vet. Med. 2018;39:30–32.</Citation></Reference><Reference><Citation>Chun X., Jianchun W., Zhiguang W., Ming W., Yupu G. Molecular cloning and sequence analysis of the type-I IFN from Beijing duck. Acta. Vet. Zoot. Sina. 2000;6:567–570.</Citation></Reference><Reference><Citation>Gao P., Xiang B., Li Y., Li Y., Sun M., Kang Y., Xie P., Chen L., Lin Q., Liao M., et al. Therapeutic Effect of Duck Interferon-Alpha Against H5N1 Highly Pathogenic Avian Influenza Virus Infection in Peking Ducks. J. Interf. Cytokine Res. 2018;38:145–152. doi: 10.1089/jir.2017.0116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2017.0116</ArticleId><ArticleId IdType="pubmed">29638205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan X.F., Lin C.Y., Yang T.Y., Shi X.J., Xia C. Molecular cloning and expression of Peking duck IFN-α gene. Chin. J. Vet. Med. 2004;12:11–13.</Citation></Reference><Reference><Citation>Schultz U., Summers J., Staeheli P., Chisari F.V. Elimination of Duck Hepatitis B Virus RNA-Containing Capsids in Duck Interferon-Alpha-Treated Hepatocytes. J. Virol. 1999;73:5459–5465. doi: 10.1128/JVI.73.7.5459-5465.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.7.5459-5465.1999</ArticleId><ArticleId IdType="pmc">PMC112602</ArticleId><ArticleId IdType="pubmed">10364293</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R., Chen J., Zhang J., Yang Y., Li P., Lan J., Xie Z., Jiang S. Novel duck hepatitis A virus type 1 isolates from adult ducks showing egg drop syndrome. Veter. Microbiol. 2018;221:33–37. doi: 10.1016/j.vetmic.2018.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2018.05.023</ArticleId><ArticleId IdType="pubmed">29981705</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian S., Xu C., Yao W.B. Research progress of long acting interferon. China Biotech. 2010;30:122–127.</Citation></Reference><Reference><Citation>Cheng T.Y., Jin W.W., Gao X.D. Progress of Modifying Interferon by Protein Engineering. World Notes Antibiot. 2011;32:156–160.</Citation></Reference><Reference><Citation>Meyer D.E., Chilkoti A. Genetically Encoded Synthesis of Protein-Based Polymers with Precisely Specified Molecular Weight and Sequence by Recursive Directional Ligation: Examples from the Elastin-like Polypeptide System. Biomacromolecules. 2002;3:357–367. doi: 10.1021/bm015630n.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bm015630n</ArticleId><ArticleId IdType="pubmed">11888323</ArticleId></ArticleIdList></Reference><Reference><Citation>Urry D.W. Free energy transduction in polypeptides and proteins based on inverse temperature transitions. Prog. Biophys. Mol. Biol. 1992;57:23–57. doi: 10.1016/0079-6107(92)90003-O.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0079-6107(92)90003-O</ArticleId><ArticleId IdType="pubmed">1549698</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay J.A., Chilkoti A. Temperature sensitive peptides: Engineering hyperthermia-directed therapeutics. Int. J. Hyperth. 2008;24:483–495. doi: 10.1080/02656730802149570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02656730802149570</ArticleId><ArticleId IdType="pmc">PMC2820342</ArticleId><ArticleId IdType="pubmed">18608590</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J., Wang G., Liu X., Gao W. Enhancing Pharmacokinetics, Tumor Accumulation, and Antitumor Efficacy by Elastin-Like Polypeptide Fusion of Interferon Alpha. Adv. Mater. 2015;27:7320–7324. doi: 10.1002/adma.201503440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201503440</ArticleId><ArticleId IdType="pubmed">26463662</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Tan X., Zong Y., Lu H., Zhang X., Xia X., Sun H. Enhancing purification and plasma stability of porcine interferon-α/γ by fusion to elastin-like polypeptide. Veter. Immunol. Immunopathol. 2018;203:60–64. doi: 10.1016/j.vetimm.2018.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetimm.2018.08.003</ArticleId><ArticleId IdType="pubmed">30243375</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W.J., Wu Q., Xu B., Zhang X.Y., Xia X.L., Sun H.C. Single-step purification of recombinant proteins using elastin-like peptide-mediated inverse transition cycling and self-processing module from Neisseria meningitides FrpC. Protein Expr. Purif. 2014;98:18–24. doi: 10.1016/j.pep.2014.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pep.2014.02.016</ArticleId><ArticleId IdType="pubmed">24607361</ArticleId></ArticleIdList></Reference><Reference><Citation>Grote A., Hiller K., Scheer M., Münch R., Nörtemann B., Hempel D.C., Jahn D. JCat: A novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 2005;33:526–531. doi: 10.1093/nar/gki376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki376</ArticleId><ArticleId IdType="pmc">PMC1160137</ArticleId><ArticleId IdType="pubmed">15980527</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborn B.L., Olsen H.S., Nardelli B., Murray J.H., Zhou J.X.H., Garcia A., Moody G., Zaritskaya L.S., Sung C. Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys. J. Pharmacol. Exp. Ther. 2002;303:540–548. doi: 10.1124/jpet.102.037002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.102.037002</ArticleId><ArticleId IdType="pubmed">12388634</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z.P., Liu Y., Luo F., Mei X.G. Investigation on tolerability and safety of interferonα-2b dry powder inhalers in rats. Pharm. J. Chin. PLA. 2010;26:393–395.</Citation></Reference><Reference><Citation>Wang Y., Zhu S., Hong W., Wang A., Zuo W. A multiplex PCR for detection of six viruses in ducks. J. Virol. Methods. 2017;248:172–176. doi: 10.1016/j.jviromet.2017.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2017.07.004</ArticleId><ArticleId IdType="pubmed">28728835</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian S., Li Q., Yao W., Xu C. Construction and characterization of a potent, long-lasting recombinant human serum albumin-interferon α1 fusion protein expressed in Pichia Pastor. Protein Expr. Purif. 2013;90:124–128. doi: 10.1016/j.pep.2013.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pep.2013.05.002</ArticleId><ArticleId IdType="pubmed">23748141</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaberc-Porekar V., Zore I., Podobnik B., Menart V. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr. Opin. Drug Discov. Dev. 2008;11:242–250.</Citation><ArticleIdList><ArticleId IdType="pubmed">18283612</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y. Self-cleaving fusion tags for recombinant protein production. Biotechnol. Lett. 2011;33:869–881. doi: 10.1007/s10529-011-0533-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10529-011-0533-8</ArticleId><ArticleId IdType="pubmed">21267760</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummins J.M., Beilharz M.W., Krakowka S. Oral use of interferon. J. Interferon Cytokine Res. 1999;19:853–857. doi: 10.1089/107999099313352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/107999099313352</ArticleId><ArticleId IdType="pubmed">10476928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R., Yang Y., Lan J., Xie Z., Zhang X., Jiang S. Evidence of possible vertical transmission of duck hepatitis A virus type 1 in ducks. Transbound. Emerg. Dis. 2020;68:267–275. doi: 10.1111/tbed.13708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tbed.13708</ArticleId><ArticleId IdType="pubmed">32598568</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>